MX2015000754A - Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. - Google Patents
Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.Info
- Publication number
- MX2015000754A MX2015000754A MX2015000754A MX2015000754A MX2015000754A MX 2015000754 A MX2015000754 A MX 2015000754A MX 2015000754 A MX2015000754 A MX 2015000754A MX 2015000754 A MX2015000754 A MX 2015000754A MX 2015000754 A MX2015000754 A MX 2015000754A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acids
- proteins
- antibodies
- btnl3 proteins
- btnl3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
La invención proporciona proteínas BTNL3 novedosas, que incluyen multímeros, fragmentos, proteínas de fusión, y variantes. Además, se proporcionan los anticuerpos que se pueden unir a las proteínas BTNL3 y los ácidos nucleicos que codifican para las proteínas BTNL3. También se proporcionan los métodos para producir las proteínas BTNL3 utilizando estos ácidos nucleicos. Se describen, los usos para las proteínas BTNL3, y los agonistas o antagonistas de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261673639P | 2012-07-19 | 2012-07-19 | |
PCT/US2013/051097 WO2014015148A1 (en) | 2012-07-19 | 2013-07-18 | Human btnl3 proteins, nucleic acids, and antibodies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015000754A true MX2015000754A (es) | 2015-04-16 |
MX366178B MX366178B (es) | 2019-07-01 |
Family
ID=48906512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015000754A MX366178B (es) | 2012-07-19 | 2013-07-18 | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. |
Country Status (8)
Country | Link |
---|---|
US (3) | US20150166630A1 (es) |
EP (1) | EP2875046B1 (es) |
JP (5) | JP6448056B2 (es) |
CN (1) | CN104703999A (es) |
AU (3) | AU2013292510A1 (es) |
CA (1) | CA2878400A1 (es) |
MX (1) | MX366178B (es) |
WO (1) | WO2014015148A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2221063A1 (en) | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
HRP20231525T1 (hr) | 2009-02-20 | 2024-03-15 | Astellas Pharma Inc. | Postupci i pripravci za dijagnozu i liječenje raka |
EP3689911A1 (en) | 2009-11-11 | 2020-08-05 | Ganymed Pharmaceuticals GmbH | Antibodies specific for claudin 6 (cldn6) |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
RS58087B1 (sr) | 2011-05-13 | 2019-02-28 | Ganymed Pharmaceuticals Gmbh | Antitela za lečenje kancera koji eksprimira klaudin 6 |
WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
CN107630085B (zh) * | 2017-10-12 | 2020-09-29 | 王丽 | 分子标志物在男性骨质疏松中的应用 |
CA3102349A1 (en) * | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
US11098093B2 (en) | 2019-01-07 | 2021-08-24 | Shattuck Labs, Inc. | Heterodimeric proteins for modulating gamma delta T cells |
WO2020146393A1 (en) | 2019-01-07 | 2020-07-16 | Shattuck Labs. Inc. | Heterodimeric proteins for modulating gamma delta t cells |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
DE3909708A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
WO1999031241A1 (en) | 1997-12-17 | 1999-06-24 | Immunex Corporation | Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000032823A1 (en) | 1998-12-02 | 2000-06-08 | Phylos, Inc. | Dna-protein fusions and uses thereof |
CA2351346C (en) | 1998-12-10 | 2015-09-01 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
AU2002211658A1 (en) | 2000-10-13 | 2002-04-22 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
WO2004058986A2 (en) | 2002-12-23 | 2004-07-15 | Immunex Corporation | Btl-ii nucleic acids, proteins, and antibodies |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
EP1702622A1 (en) | 2005-03-18 | 2006-09-20 | CONARIS research institute AG | Soluble BTNL2 protein useful to inhibit inflammatory disorders |
TW200732350A (en) | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
US20100120627A1 (en) | 2006-08-02 | 2010-05-13 | Abdelmajid Belouchi | Genemap of the human genes associated with psoriasis |
ES2774337T3 (es) | 2008-01-07 | 2020-07-20 | Amgen Inc | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
EP2221063A1 (en) * | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
EP2556086B1 (en) * | 2010-04-09 | 2015-03-04 | Amgen Inc. | Btnl9 proteins, nucleic acids, and antibodies and uses thereof |
-
2013
- 2013-07-18 CN CN201380038216.0A patent/CN104703999A/zh active Pending
- 2013-07-18 MX MX2015000754A patent/MX366178B/es active IP Right Grant
- 2013-07-18 JP JP2015523255A patent/JP6448056B2/ja active Active
- 2013-07-18 AU AU2013292510A patent/AU2013292510A1/en not_active Abandoned
- 2013-07-18 EP EP13742802.5A patent/EP2875046B1/en active Active
- 2013-07-18 WO PCT/US2013/051097 patent/WO2014015148A1/en active Application Filing
- 2013-07-18 CA CA2878400A patent/CA2878400A1/en active Pending
- 2013-07-18 US US14/407,904 patent/US20150166630A1/en not_active Abandoned
-
2017
- 2017-10-31 JP JP2017210450A patent/JP2018015009A/ja not_active Withdrawn
-
2018
- 2018-01-09 AU AU2018200171A patent/AU2018200171A1/en not_active Abandoned
-
2019
- 2019-01-24 US US16/256,951 patent/US11459370B2/en active Active
- 2019-10-16 AU AU2019250154A patent/AU2019250154B2/en active Active
- 2019-12-19 JP JP2019228946A patent/JP2020039369A/ja not_active Withdrawn
-
2021
- 2021-12-28 JP JP2021214198A patent/JP2022040181A/ja not_active Withdrawn
-
2022
- 2022-08-23 US US17/893,998 patent/US20230192802A1/en active Pending
-
2023
- 2023-11-10 JP JP2023192170A patent/JP2023184751A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2013292510A1 (en) | 2015-02-05 |
AU2018200171A1 (en) | 2018-02-01 |
MX366178B (es) | 2019-07-01 |
WO2014015148A1 (en) | 2014-01-23 |
EP2875046A1 (en) | 2015-05-27 |
US11459370B2 (en) | 2022-10-04 |
JP2022040181A (ja) | 2022-03-10 |
JP2015524413A (ja) | 2015-08-24 |
JP2020039369A (ja) | 2020-03-19 |
US20230192802A1 (en) | 2023-06-22 |
US20150166630A1 (en) | 2015-06-18 |
JP2023184751A (ja) | 2023-12-28 |
AU2019250154A1 (en) | 2019-10-31 |
JP6448056B2 (ja) | 2019-01-09 |
JP2018015009A (ja) | 2018-02-01 |
AU2019250154B2 (en) | 2021-04-22 |
US20190169259A1 (en) | 2019-06-06 |
CN104703999A (zh) | 2015-06-10 |
EP2875046B1 (en) | 2020-02-26 |
CA2878400A1 (en) | 2014-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
MX366178B (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
EA201492101A1 (ru) | Антитела против fcrn | |
PH12014502527A1 (en) | St2 antigen binding proteins | |
MX2015008446A (es) | Composiciones de proteinas de union multivalentes. | |
MX2019007921A (es) | Nuevos agentes de union a ha. | |
MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
PH12016500275B1 (en) | Antibodies | |
EA201400964A1 (ru) | Cx3cr1-связывающие полипептиды | |
MY184037A (en) | Antibodies to bradykinin b1 receptor ligands | |
PH12016500753B1 (en) | Antibodies specific to fcrn | |
PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
WO2014151834A3 (en) | Methods and compositions relating to anti-ccr7 antigen binding proteins | |
MX2015014198A (es) | Anticuerpos cuyo objetivo es m-csf. | |
MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |